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ABSTRACT
Colorectal cancer (CRC) therapy mainly relies on the use of conventional chemotherapeutic drugs
combined, in a subset of patients, with epidermal growth factor receptor [EGFR]-targeting agents.
Although CRC is considered a prototype of a cancer stem cell (CSC)-driven tumor, the effects of both
conventional and targeted therapies on the CSC compartment are largely unknown. We have opti-
mized a protocol for colorectal CSC isolation that allowed us to obtain CSC-enriched cultures from
primary tumor specimens, with high efficiency. CSC isolation was followed by in vitro and in vivo val-
idation, genetic characterization, and drug sensitivity analysis, thus generating panels of CSC lines
with defined patterns of genetic mutations and therapy sensitivity. Colorectal CSC lines were poly-
clonal and maintained intratumor heterogeneity in terms of somatically acquired mutations and
differentiation state. Such CSC-enriched cultureswere used to investigate the effects of both conven-
tional and targeted therapies on the CSC compartment in vivo and to generate a proteomic picture of
signaling pathways implicated in sensitivity/resistance to anti-EGFRagents.WeproposeCSC lines as a
sound preclinical framework to test the effects of therapies in vitro and in vivo and to identify novel
determinants of therapy resistance. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:511–523
SIGNIFICANCE
Colorectal cancer stem cells (CSCs) have been shown to be responsible for tumor propagation,
metastatic dissemination, and relapse. However, molecular pathways present in CSCs, as well
as mechanisms of therapy resistance, are mostly unknown. Taking advantage of genetically char-
acterized CSC lines derived from colorectal tumors, this study provides an extensive analysis of
CSC response to EGFR-targeted therapy in vivo and an overview of factors implicated in therapy
response or resistance. Furthermore, the implementation of a biobank of molecularly annotated
CSC lines provides an innovative resource for future investigations in colorectal cancer.
INTRODUCTION
Colorectal cancer (CRC) represents one of thema-
jor causes of cancer-related deaths worldwide.
Although the use of epidermal growth factor re-
ceptor (EGFR)-targeted agents has improved sur-
vival in a subset of patients with CRC, even
sensitive tumors invariably develop therapy re-
sistance, mainly because of the emergence of
mutations that confer epidermal growth factor
(EGF)-independent proliferation [1]. The hierarchi-
calstructureofCRCisdominatedbycancerstemcells
(CSCs), which have been shown to be responsible
for tumor progression, metastasis, chemotherapy
resistance, and tumor relapse [2]. Recent studies
provided significant advancements in identifying
CSC derivation, phenotype, and function, indicat-
ing a tight link between CSC features and patient
prognosis [3–5]. However, the effect of antican-
cer drugs on the CSC compartment in vivo and
the molecular mechanisms responsible for CSC
resistance remain largely unexplored. We have
implemented a protocol for CSC isolation as mul-
ticellular spheroids, followedby genomic, proteo-
mic, and functional analyses of drug sensitivity.
This method allowed us to generate genomic
and proteomic profiles of CSCs sensitive and
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resistant to anti-EGFR agents, thus identifying differentially reg-
ulated factors that can contribute to therapy response. CRC tu-
mor spheroids were used to investigate the in vivo effect of
conventional and targeted therapies on the CSC compartment,
providing evidence that anti-EGFR therapy can affect CSC number
and can counteract CSC expansion induced by chemotherapy. Fi-
nally, we analyzed the sensitivity of KRASwt and KRASmut CSC lines
to a panel of targeted pathway inhibitors as single agents and in
combination with anti-EGFR. Altogether, the generation of a mo-
lecularly annotated bank of CSC lines represents a resource for
future investigations of the molecular basis of CRC and, in partic-
ular, for studies on the role of CSC in therapy resistance.
MATERIAL AND METHODS
CSC Isolation and Culture
Fresh human colorectal cancer tissues were obtained in accor-
dance with the standards of the ethics committee on human ex-
perimentation of the Istituto Superiore di Sanita` (authorization
no. CE5ISS 09/282). Tissue samples were collected by a sur-
geon or a pathologist immediately after each patient’s sur-
gery, quickly washed 2–3 times in cold saline, then transferred
in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher
Scientific, Carlsbad, CA, https://www.thermofisher.com) contain-
ing 3% penicillin-streptomycin-amphotericin B solution (Lonza
Group, Walkersville, MD, http://www.lonza.com), and kept in this
medium at 4°C until processing within 24–48 hours. For tissue dis-
sociation, CRC samples were first washed 3–4 times in phosphate-
bufferedsaline (PBS), thencutby forcepsand/or scalpel inpiecesof
approximately 0.5mmor smaller. Fragmentswere furtherwashed
twice by centrifugation at 150g for 3 minutes, then incubated in
DMEM (Thermo Fisher Scientific) with 1.5mg/ml collagenase type
II (Thermo Fisher Scientific) and 20 mg/ml DNAse (Roche Diagnos-
tics, Indianapolis, IN, https://usdiagnostics.roche.com) for 1 hour
at 37°Cunder shaking. Thecell suspensionwas then filtered through
a 100-mmnylonmesh, andwashedby 2 further centrifugation steps
in DMEM. Finally, pellets containing cells, cell clusters, and tissue
fragmentswere resuspended inCSCmedium[6] supplementedwith
10mMnicotinamide, 1mMY-27632 (both from Sigma-Aldrich, St.
Louis, MO, http://www.sigmaaldrich.com), 20 ng/ml human
EGF and 10 ng/ml human basic fibroblast growth factor (both
from PeproTech, London, U.K., https://www.peprotech.com).
The resulting suspension was plated in ultra-low attachment tis-
sue culture flasks (Corning Costar, Cambridge, MA, https://www.
corning.com), and cultured in humidified atmosphere at 37°C,
5% CO2. Every 2 to 3 days, half of the culture medium was
refreshed. In the first weeks of culture, cells were periodically
centrifuged at 150g for 5 minutes, and the pellet was delicately
passed 3 to 5 times through a 200 ml Gilson pipette tip in a small
volumeofmedium; then the finalmediumvolumewas added and
cells were replated. Clusters of proliferating cells became evident
after a variable lengthof time, ranging from5 to7days to3weeks.
Bacterial contamination usually developed in approximately 20%
of specimenswithin 3–4 days of culture. Cultures inwhich no pro-
liferating clusters were detected after 4 weeks were discarded.
Regular culture splitting (1:2)was usually needed after 3–6weeks
from isolation. Spheroidswere then passagedweekly bymechan-
ical dissociation or by incubation for 3–5minutes at 37°Cwith Try-
pLE Express (Thermo Fisher). Cultures were usually used to
prepare frozen stocks around the fifth passage and used for in
vitro and in vivo experiments within the 12th passage.
Animal Procedures
All animal procedureswereperformedaccording to the Italianna-
tional animal experimentation guidelines (D.L.116/92) upon ap-
proval of the experimental protocol by the Italian Ministry of
Health’s Animal Experimentation Committee. We used 4- to
6-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
(The Jackson Laboratory, Bar Harbor, ME, https://www.jax.org)
were used for all the validations and experiments. For CSC valida-
tion, 53 105 cells were injected subcutaneously in the flank of 3
replicate mice, in 100ml 1:1 PBS/Matrigel (BD, Franklin Lakes, NJ,
http://www.bd.com). In all the CSCs validated, xenografts were
detectable within 3–5 weeks in at least 2 out of 3 mice. Palpable
xenografts were extracted, formalin-fixed, and paraffin-
embedded. Hematoxylin and eosin-stained sections were subse-
quently evaluated by a pathologist in comparisonwith the human
tumor of origin. For drug testing, 5 3 105 CSCs were inoculated
subcutaneously as described above. Tumors were measured
twice weekly by an external digital caliper, and volumes were cal-
culated using the following formula:p/63d23D,where d andD
represent shorter and longer tumormeasurements, respectively.
Drug treatments were started after tumor establishment
(100–150 mm3). Mice were treated with 10 mg/kg cetuximab
(Merck KGaA, Darmstad, Germany, http://www.emdgroup.
com) intravenously twice weekly. Irinotecan (Pfizer, New York,
NY, http://www.pfizer.com) was administered intraperitoneally
weekly at the dose of 15 mg/kg. Control animals were treated
with vehicle only. For secondary transplantation experiments, tu-
mors (six tumors per treatment group) were harvested and disso-
ciated into single cells. For each individual tumor, cells were
injected into secondary mice at serial doses ranging from 10 to
103. Mice were recorded as negative when no graft was observed
after 24 weeks from inoculation.
Flow Cytometry
Single cells dissociated from spheroids or xenografts were
washed with PBS/bovine serum albumin (BSA) 1% and incubated
with the appropriate dilution of control or specific antibody in the
same buffer for 45 minutes at 4°C. Fluorescence intensity of la-
beled cells was evaluated by a FACSCanto instrument (BD). Anti-
bodies and controls used for routine analysis and experiments
reported in the study were the following: anti-EpCAM-APC,
anti-EpCAM-PE, and isotype controls mouse IgG2b-APC, mouse
IgG1-APC (all from BD); mouse IgG1-PE, anti-Lgr5-PE, and anti-
CD133-PE (Miltenyi Biotec, Bergisch Gladbach, Germany,
http://www.miltenyibiotec.com); anti CD44v6-APC (R&D Sys-
tems,Minneapolis, MN, https://www.rndsystems.com).We al-
ways added 7-aminoactinomycin D (10 mg/ml; BD) to exclude
dead cells.
Clonogenicity Assay
The clonogenic units in xenograft-derived cells were assessed by
plating 500 cells/ml perwell in triplicate in 24-well plates contain-
ing a soft agar bilayer (0.3% topand0.4%bottom layer; SeaPlaque
Agarose; Cambrex, East Rutherford, NJ, http://www.cambrex.
com). Cultures were incubated in humidified atmosphere at
37°C and 5% CO2 for 21 days. Colonies were stained with crystal
violet (0.01% in 10:1 methanol to water), and counted under a
light microscope. Data represent the percentage of colonies nor-
malized to the number of cells plated.
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Reverse-Phase Protein Array Analysis
CSC pellets were lysed in buffer containing T-PER reagent (Thermo
Fisher Scientific), 300 mM NaCl, 2 mM Pefabloc (Roche), 1 mM
orthovanadate, 5 mg/ml aprotinin, 5 mg/ml pepstatin A, and
5 mg/ml leupeptin (all from Sigma-Aldrich), and were incubated
on ice for 20 minutes. Samples were centrifuged at 10,000g for
5 minutes, supernatants were transferred to fresh tubes and total
protein concentrationwasmeasured by Bradford reagentmethod
(Coomassie protein assay; Thermo Fisher Scientific). Lysates were
thendiluted for printing in extraction buffer containing 50%T-PER,
47.5% 23 sodium dodecyl sulfate, and 2.5% b-mercaptoethanol
(all from Thermo Fisher Scientific) to final concentrations of
0.5 mg/ml.
All samples were printed in technical triplicate spots and in
four-point twofold dilution curve format onto nitrocellulose-
coated glass slides (GRACE Bio-Laboratories, Bend, OR, http://
www.gracebio.com). Reference standard lysates (i.e., HeLa plus
pervanadate (BD), A431 plus EGF (BD), Jurkat plus etoposide (Cell
Signaling Technology, Danvers, MA, http://www.cellsignal.com),
and Jurkat plus calyculin A (Cell Signaling) were printed in
10-point decreasing mixtures of treated to untreated sample as
procedural controls and as positive controls for antibody staining.
Each reference standard curve was printed in technical triplicate
at a final concentration of 0.5 mg/ml. An Aushon 2470 arrayer
equipped with 185-mm pins (Aushon Biosystems, Billerica, MA,
https://www.aushon.com) was used to print samples/slides
according to the manufacturer’s instructions.
A selected subset of the printedmicroarray slideswas stained
with Sypro Ruby protein blot stain (Thermo Fisher) to estimate
sample total protein concentration, and the remaining slides
were stored under desiccated conditions at220°C. Immediately
before antibody staining, printed slides were treatedwith 13 Re-
Blot Mild Solution (EMP Millipore, Temecula, CA, http://www.
emdmillipore.com) for 15 minutes, washed for 5 minutes twice
with PBS and incubated for 1 hour in blocking solution containing
2% I-Block (Applied Biosystems, Foster City, CA, http://www.
appliedbiosystems.com) and 0.1% Tween-20 in PBS. Immunostain-
ing was carried out using a tyramide-biotin signal amplification kit
(Dako, Carpinteria, CA, http://www.dako.com). Arrays were probed
with a library of 40 antibodies against antigens to either total,
cleaved, or phosphorylated protein targets. Primary antibody bind-
ing was detected using a biotinylated goat anti-rabbit immunoglob-
ulin G (IgG) H+L (1:7,500; Vector Laboratories, Burlingame, CA,
https://www.vectorlabs.com) or rabbit anti-mouse Ig (1:10; Dako)
followed by streptavidin-conjugated IRDye680LT fluorophore (LI-
COR Biosciences, Lincoln, NE, https://www.licor.com). Primary anti-
bodies had undergone pre- and post-reverse-phase protein array
(RPPA) validation for single-band specificity byWesternblot analysis
using complex cellular lysates. Negative control slides were incu-
bated with secondary antibody only and included in each staining
run.
All Sypro- and immunostained slides were scanned using a
Tecan Power Scanner (Tecan Group, Mannedorf, Switzerland,
http://www.tecan.com) at 5-mm resolution. Acquired images
were analyzed with MicroVigene version 5.2 (VigeneTech,
Carlisle, MA, http://www.vigenetech.com) for spot detection, lo-
cal background subtraction, negative control subtraction, repli-
cate averaging, and total protein normalization. The packages
ggplot2, Bioconductor, coin, and gplots of the “R” software for
statistical computing (https://www.r-project.org) [7] were used
to carry out quality control, internal standardization, two-way hi-
erarchical clustering (Spearman correlation distance and Ward
method), and two-sample Wilcoxon rank-sum tests (significance
cutoff set at .05).
Western Blotting
Cell lysateswere obtained from approximately 53 105 spheroid
cells by incubation of cell pellets in 1% NP40 lysis buffer (20 mM
TrisHCl pH 7.2; 200mMNaCl; 1%NP40) supplementedwith pro-
tease inhibitor cocktail and phosphatase inhibitor cocktails I and
II (all from Sigma-Aldrich). Lysate concentrations were deter-
mined by Bradford assay (Bio-Rad Laboratories, Hercules, CA,
http://www.bio-rad.com) and equal amounts of proteins were
loaded on a gradient precast gel (4%–12% or 3%–8%; Thermo
Fisher), then transferred to nitrocellulose membranes (GE
Healthcare, Piscataway, NJ, http://www.gelifesciences.com).
Blots were blocked with TBST 5% nonfat dry milk and incubated
overnight at 4°C with primary antibodies, then incubated for
45minuteswith secondaryhorseradishperoxidase-conjugatedan-
tibodies dissolved in TBST 1%BSA. Chemiluminescent signalswere
detectedwith Super SignalWest Pico (Thermo Fisher Scientific).
Monoclonal anti-a-tubulin and monoclonal anti-b-actin were
from Sigma-Aldrich; other antibodies were from Cell Signaling
Technology.
Viability Assay and Drug Screening
CSC viability upon treatmentwith cetuximab and/or kinase inhib-
itorswasdeterminedbyCellTiter-Glo luminescent cell viability as-
say (Promega, Madison, WI, http://www.promega.ca) according
to the manufacturer’s directions. Briefly, CSCs (2.5–3 3 103 per
well) were dissociated with TrypLE Express, seeded in 96-well
plates (six replicates per experimental point) in CSC medium,
and incubated in a humidified atmosphere at 37°C, 5%CO2. Lumi-
nescence was detected with a DTX880 multimode microplate
reader (Beckman Coulter, Brea, CA, https://www.beckmancoulter.
com). Cetuximab was always used at a concentration of 100 mg/ml
and kinase inhibitors (Selleck Chemicals, Houston, TX, http://www.
selleckchem.com) at 100 nM.
Statistical Analysis
Statistical significance of data was evaluated by analysis of vari-
ance (ANOVA) and Bonferroni posttests or by unpaired Student’s
t test withWelch’s correction, depending on the experiment. Sta-
tistical significance up to .05 was accepted. Statistical analyses
were performed using GraphPad Prism version 4.0 for Windows
(GraphPad Software, SanDiego, CA, http://www.graphpad.com).
Serial transplantation/limiting dilution assays were analyzed by
extreme limiting dilution analysis (ELDA) software [8].
DNA Extraction and Short Tandem Repeats Analysis
Genomic DNAwas obtained by CSCs and patient-matched nontu-
moral tissues (Dnasy mini kit; Qiagen, Limburg, The Netherlands,
https://www.qiagen.com). Short tandem repeats (STR) analysis
was performed by using the AmpFlSTRIdentifiler Plus kit (Applied
Biosystems). A unique STR profile was generated for each CSC
line, which was used to monitor purity of the line over time
and to confirm its matching with the biological material available
for each patient included in the study.
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Whole Exome Sequencing, Data Analysis, and Validation
Target enrichment was performed using in-solution technology
(NimbleGen SeqCap EZ Library version 3.0; Roche) and the result-
ing target libraries were sequenced by Illumina sequencing tech-
nology (HiSeq2000; Illumina, SanDiego,CA, http://www.illumina.
com). Raw image files were processed by Illumina base-calling
software (CASAVA 1.7) using default parameters. Paired-end
reads were aligned to the human genome (UCSC GRCh37/hg19;
University of California, Santa Cruz, Bioinformatics, Santa Cruz,
CA, https://genome.ucsc.edu) with the Burrows-Wheeler aligner
(version 0.7.10) [9]. Presumed polymerase chain reaction dupli-
cates were removed using Picard’s MarkDuplicates (Broad Insti-
tute, Cambridge, MA, http://broadinstitute.github.io/picard).
The Genome Analysis Toolkit (GATK 3.3; Broad Institute) [10]
was used for realignment of sequences encompassing insertions
and deletions (indels) and for base quality recalibration. Somatic
single-nucleotide variants were detected using Mutect software
version 1.1.6 (Broad Institute) [11], and small indels were identi-
fied through a comparison between indels called in individual CSC
lines and their matched nontumoral samples by means of the
GATK Haplotype Caller algorithm [12], applying the following
quality filters: quality score greater than 100 and quality-by-
depth score greater than 1.5. Indels below these thresholds or
resulting from 4 or more reads having ambiguous mapping (this
number being greater than 10% of all aligned reads) were dis-
carded. The resulting single-nucleotide variants and small indels
were annotated by SnpEff version 3.6 (http://snpeff.sourceforge.
net) [13] and dbNSFP2.8 [14] in terms of functional impact of var-
iants (i.e., missense or nonsense; coding or noncoding; location
with respect to exon-intron junction, depth, reference/variant
reads ratio, single nucleotide polymorphism database identifica-
tion, amino acid change, and position; cancer association data;
and structural/functional impact). Variant validation and geno-
typingwereperformedbySanger sequencing.Ampliconsweredi-
rectly sequenced using the ABI BigDye Terminator Sequencing kit
(Applied Biosystems) and an automated capillary sequencer (ABI
3500; Applied Biosystems). Sequence electropherograms were
analyzed using Sequencing Analysis Software version 5.4 (Applied
Biosystems).
RESULTS
A Protocol for the Isolation, Profiling, and Functional
Analysis of Colorectal CSC
Previous studies by our and other laboratories reported thatmul-
ticellular spheroid suspensions enriched in CSCs could be
obtainedby the selective cultureof cells extracted fromcolorectal
tumor specimens in serum-free media [6, 15–18]. We improved
previous culture methods through supplementation with factors
identified by Sato et al. (nicotinamide and Y-27632), which are
also essential for the in vitro growth of normal intestinal stem
cells [19], reaching approximately 40% of success in the genera-
tion of CSC cultures from tumor specimens (supplemental online
Table 1). It is of note that our method for the generation of CSC-
enriched cultures (called “CSC lines” hereafter) avoids previous in
vivo passages that could exert a selective pressure on CRC cells by
allowing the exclusive growth of clones compatible with the mu-
rine microenvironment. The resulting spheroid cultures are rou-
tinely validated for theexpressionof the stemcellmarkersCD133,
Lgr5, and CD44v6 (which are usually present respectively at
greater than 70%, approximately 10%, and approximately 30%
positivity) and for their capability to reproduce a histological copy
of the original patient tumorwhen inoculated in immunocompro-
mised mice (Fig. 1; supplemental online Fig. 1), which, together,
provide evidence for an enrichment in stem/progenitor cells. The
high content of stem/progenitor cells in CSC lines is further cor-
roborated by the elevated percentage of cells expressing GPF
under the TCF/LEF promoter (TOP-GFP), which is an indica-
tor of high WNT activity and is a functional marker of CSCs
(supplemental online Fig. 2) [20]. Having fulfilled the in vitro
and in vivo validation steps, CSC lines undergo identity verifica-
tion through STR analysis and are subsequently frozen in a con-
tinuously expanding CSC bank comprising more than 60 CSC
lines at the time of writing. Cells are then used for molecular
analyses such as whole exome sequencing (WES), RPPA, and
drug sensitivity tests (Fig. 1). Moreover, banked CSC lines can
be used to produce subcutaneous tumor xenografts andmodels
of tumor metastasis. The latter can be generated by injecting
CSC lines transducedwith a luciferase-encoding lentiviral vector
either in the colon wall, where they give rise to a colon tumor
that, in turn, produces spontaneous liver metastases, or in the
spleen, where they generate a local tumor and subsequent liver
metastases [21] (supplemental online Fig. 3).
Mutational Layout and Genomic Profiling of Colorectal
CSC Lines
To provide an exhaustive profiling of somatically acquired muta-
tions present in CSC lines, WES was systematically carried out on
genomic DNA extracted from CSCs and patient-matched nontu-
moral tissues, as described in Materials and Methods. Approxi-
mately 90 million high-quality paired end reads, corresponding
to 8Gb, were obtained for each sample. Themedian depth across
all samples was 743. On average, 99% of all targeted bases were
covered by at least 1 read, and 91% were covered by at least 20
reads (supplemental online Table 2). WES data analysis was di-
rected to identify andannotate somatic variantswithin the coding
sequence and flanking intronic regions, as well as copy-number
variations and loss of heterozygosity regions. In a representative
sampleof 24CSC lines, theaveragenumberof identified function-
ally relevant somatic variants (i.e., nonsynonymous and splice site
changes) was 808, displaying marked differences among individ-
ual CSCs (supplemental online Table 2). Based on mutation rate
per Mb, CSCs could be distinguished in hypermutated (more
than 10 mutations/Mb) and nonhypermutated (fewer than 10
mutations/Mb) (Fig. 2A). The presence of both hypermutated
and nonhypermutated CSC lines and their relative frequency
(25%, slightly higher than 16% reported by the Cancer Genome
Atlas Network [22]) implies a balanced generation of CSC cultures
with respect to mutational rates.
Analysis of the most common CRC mutations (Fig. 2B;
supplemental online Table 3) revealed an occurrence of KRAS,
BRAF, PIK3CA, APC, TP53, and SMAD4 mutations roughly corre-
sponding to those reported in theCOSMIC database, thus indicat-
ing the absence of gross mutational biases in the method of CSC
generation. Also, a differential prevalence of genemutations was
documented in the hypermutated and nonhypermutated CSC
lines (Fig. 2C); this was consistent with previously reportedmuta-
tional profiles in CRC [22]. Formost lines, the observed difference
in the frequency distribution profiles of individual germline-
inherited and somatically acquired variants supported their
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polyclonality (Fig. 3A). CSCs also differed in their mutational sig-
natures, including the presence of distinctive signatures associ-
ated with colon cancer and defective mismatch repair [23] (Fig.
3B). Overall, these observations indicate that CSC lines faithfully
reproduce thegenomic complexity of colorectal tumors, thus rep-
resenting a valuable tool to discover novel correlations between
genetic mutations and therapy outcomes.
In Vitro and In Vivo Sensitivity of Colorectal CSC Lines to
EGFR Targeting
Monoclonal antibodies targeting the EGF receptor (EGFR), such
as cetuximab and panitumumab, achieve clinically significant
responses in a portion of patients with CRC with KRASwt. The
molecular pathways active in resistant tumors that drive EGFR-
independent proliferation have only been partly elucidated
[24]. We hypothesized that colorectal CSC lines would represent
a valuable model to investigate both themolecular determinants
associated with anti-EGFR response and the in vivo effects of
cetuximab on the CSC compartment. To validate this hypothesis,
we first investigated cetuximab sensitivity in 23 CSC lines in rela-
tion to KRAS and BRAFmutational status. We performed this test
in the absence of EGF, because we (supplemental online Fig. 4)
and others [25] previously verified that the effect of cetuximab
is masked by EGF normally present in CSC media, probably due
to competition for the occupancy of the EGFR extracellular
domain.
Figure 1. Workflow for cancer stem cell (CSC) isolation and banking. Newly isolated CSCs (top panel) are validated by STR identification and
matchingwith normal patient’s tissue, by tumorigenicity assessment in immunodeficientmice and xenograft comparisonwithprimary patient’s
tumor, and, finally, by stem cell marker analysis (lower left panel). Following banking, CSCs are exome sequenced, analyzed by RPPA analysis,
screened fordrug sensitivity in vitro andused toproduce xenograftmodels toallowpreclinical drug validation (lower right panel). Abbreviations:
RPPA, reverse phase proteomic array; STR, short tandem repeats analysis.
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As shown in Figure 4A, individual CSC lines displayed a vari-
able response to cetuximab treatment that was partly related
to their mutational status. CSC lines with mutated KRAS or BRAF
were all found to display partial or high resistance to anti-EGFR
treatment.Bycontrast,all the lineswithhighsensitivity tocetuximab
had wild-type KRAS and BRAF. As expected, KRASwt/BRAFwt CSCs
were also found among cetuximab-resistant lines, confirming
that othermechanisms are responsible for anti-EGFR resistance.
Then, we investigated the therapeutic response of CSC-derived
xenografts to cetuximab treatment. Figure 4B shows that a
KRASwt CSC line sensitive to cetuximab-mediated growth inhibi-
tion in vitro gives rise to cetuximab-sensitive tumors in mice.
Likewise, a KRASmut CSC line resistant to cetuximab in vitro gen-
erates resistant tumors in vivo. The correlation between CSC
Figure 2. Whole exome sequencing (WES)-based mutation profiling of cancer stem cells (CSCs). (A): WES analysis allows estimation of CSC
mutation rates, distinguishing hypermutated (more than 10mutations perMb) and nonhypermutated (fewer than 10mutations perMb) lines.
High- and low-gradeMSI is indicated by green and orange asterisks, respectively. Both silent (blue) and functionally relevant (red) somatic var-
iants are reported. (B): An OncoPrint (cBioPortal, New York, NY, http://www.cbioportal.org) showing functionally relevant intragenic lesions in
recurrently mutated genes for individual CSC lines. Half boxes and full boxes represent heterozygous and homozygous variants, respectively;
colors are used to specify the type of mutation. Asterisks indicate germline mutations; multiple hits affecting the same gene are indicated by
numbers. (C): Graphs showing the most frequently mutated genes in hypermutated (upper graph) and nonhypermutated (lower graph) CSC
lines. Abbreviation: MSI, microsatellite instability.
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sensitivity to cetuximab in vitro and tumor response in vivo (r2 =
0.86) (Fig. 4C) was confirmed by analyzing 6 additional CSC lines
(supplemental online Fig. 5) and indicates the presence of parallel
sensitivity patterns in multicellular spheroids and in CSC-derived
xenografts.
Starting from the assumption that the effect of EGFR inhibi-
tion on the CSC compartment in vivo is poorly understood, we
took advantage of xenografts derived from two cetuximab-
sensitive CSC lines (CSC 20, KRASwt/highly sensitive and CSC
15, KRASmut/medium sensitive) to investigate the effect of
cetuximab on CSCs. Mice bearing subcutaneous CSC-derived tu-
mors were treated with cetuximab, irinotecan, or with the
cetuximab-irinotecan combination and, at the end of the treat-
ment, the CSC compartment was evaluated through multiple
methods. In xenografts derived from both CSC lines, cetuximab
treatment induced a reduction of tumor growth that was pro-
portional to the cells’ sensitivity to growth inhibition ob-
served in vitro (Fig. 5A, 5B; supplemental online Fig. 5). In
xenografts derived from highly sensitive CSCs, the effect of
irinotecan was comparable to that of cetuximab, whereas in
medium-sensitive tumors, irinotecan (and the irinotecan-
cetuximab combination) was more effective than cetuximab
alone in reducing tumor growth.
Then, we assessed the size of the CSC compartment in
control and treated tumors through three different methods:
frequencyof CD44v6+ cells (Fig. 5C), ability of tumor cells to form
colonies ex vivo in semisolid culture (Fig. 5D), and functional
ability to form tumors upon serial transplantation (where CSC
frequency in control and treated tumors was calculated with
the ELDA software [8]) (Fig. 5E). Interestingly, the three stem-
cell assays all showed that irinotecan increased the proportion
of CSCs as comparedwith both vehicle-treated and cetuximab-
treated tumors, while cetuximab did not significantly change
the percentage of CSCs as compared with controls, indicating
that anti-EGFR treatment affects stem and nonstem tumor
cells to the same extent. Notably, the combination of cetuxi-
mab and irinotecan resulted in a significantly lower percent-
age of CSCs as compared with irinotecan alone, indicating that
cetuximab efficiently counteracts chemotherapy-induced CSC
selection.
Figure 3. Distribution of variant alleles in cancer stem cells (CSCs). (A): Frequency distribution patterns for the annotated germline inherited
(solid line) and somatically acquired (dashed line) variants in a representative subsetofCSC lines. (B):Mutational signaturesof the sameCSC lines
as in (A). Each signature is displayed according to the 96 substitution classification defined by the substitution class and sequence context im-
mediately 39 and 59 to the mutated base. Bars for the six types of substitutions are displayed in different colors. Abbreviation: SNV, single-
nucleotide variant.
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Figure 4. Effect of epidermal growth factor receptor inhibition on CSC spheroids andmatched xenografts. (A): CSC sensitivity to cetuximab in
EGF-deprived cultures. Cell growth is expressed as the percentage ofmaximal growth occurring in complete CSCmedium (i.e., in the presence of
20 ng/ml exogenous EGF).Mutational status for KRAS andBRAF is indicated for each CSC line. Spheroid culture viabilitywas assessed at 72 hours
by the CellTiter-Glo luminescent cell viability assay (Promega), as described in Materials and Methods. Data represent the average of three
independent experiments6 SEM. (B): Time course of cetuximab inhibition on the growth of spheroid cultures (left panels) and of tumor xe-
nografts (right panels) in representative CSC1 (KRASwt) andCSC8 (KRASmut). Spheroid viabilitywas assessedas in (A); data represent theaverage
of three independent experiments6 SEM. CSC subcutaneous xenografts were generated as described in Materials andMethods. After tumor
establishment, mice were treatedwith 10mg/kg cetuximab intravenously twice weekly. Data represent the average of 6–10 tumors per group.
For all the tests, statistical significancewas calculatedby two-tailed Student’s t test. Linear regression is shown in red. Foreach test, inhibition can
be expressed as the ratio of slopes (treated to untreated). (C): Plot of cetuximab-induced growth inhibition in spheroids versus xenografts cal-
culated for eight CSC lines (panel B; supplemental online Fig. 5). Cetuximab inhibition of CSC spheroids strongly correlates with xenograft re-
duction (r2 = .860). All calculations were done with the GraphPad Prism software. Abbreviations: CETU, cetuximab; CSC, cancer stem cell; EGF,
epidermal growth factor.
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Figure5. Effectofepidermalgrowthfactorreceptor inhibitionontheCSCcompartment invivo. (A):Effectofcetuximabandirinotecanonthegrowthof
xenograftsderived fromhighly cetuximab-responsiveCSC20andmedium-responsiveCSC15.After tumorestablishment,micewere treatedwitheither
cetuximab (10mg/kg intravenously twiceweekly) or irinotecan (15mg/kg intraperitoneallyweekly) or their combination; control animalswere treated
with vehicle only. Data represent theaverageof 8–10 tumors6 SEM (B): Tumorweight at the timeof excision. (C): Flowcytometry analysis for EpCAM/
CD44v6 on cells dissociated from xenografts in (A). Data represent the average of six xenografts for group6 SD (D): Clonogenicity assay performed ex
vivo on cells isolated from xenografts as in (A). Cells were plated in triplicate, at 500 cells/ml per dish as described inMaterials andMethods. Colonies
were scored at day 21. Data represent the average of six to eight xenografts per group6 SEM. Statistical significance in (A–D)was calculatedwith one-
wayanalysisofvariance. (E):Secondtransplantationofcellsdissociated fromxenograftsof in (A). Cellsdissociated fromindividual tumors (six tumorsper
treatment group) were retransplanted subcutaneously into secondary recipient mice. For each individual tumor, different cell doses were tested as
explained inMaterials andMethods.Micewere recorded as negativewhen no graft was observed after 24weeks from the inoculation. CSC frequency
was calculatedwith the extreme limiting dilution analysis software, as described in theMaterials andMethods. Statistical significanceof the resultswas
calculated with chi-square analysis. p, p, .05, pp, p, .01, ppp, p, .001. Abbreviations: CETU, cetuximab; CSC, cancer stem cell; IRI, irinotecan.
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Proteomic-Based Identification of Molecular Pathways
Involved in Anti-EGFR Sensitivity/Resistance
RPPA allows the simultaneous evaluation of phosphorylated,
cleaved, or unmodified proteins generating comprehensive pro-
files of pathway activation in untreated and drug-treated cells
[26]. To define the signaling pathways affected by anti-EGFR
treatment in KRASwt/anti-EGFR-sensitive and KRASmut/resistant
CSCs, we performed a RPPA analysis with 40 antibodies
(supplemental online Table 4) of 2 CSC lines with opposite cetux-
imab sensitivity at different times of treatment (Fig. 6A). Selected
significantly different endpoints (Fig. 6B) were validated by im-
munoblotting (Fig. 6C). Sensitive CSCs showedadecrease inphos-
phorylated AKT and its downstream target p70S6K upon
cetuximab treatment, in parallel with a decrease in MEK1/2,
BCL2, JAK2, and MTOR phosphorylation and in total STAT3. By
contrast, resistant CSC showed variable levels of phospho-AKT,
phospho-p70S6K, phospho-MTOR, and total MTOR, which, how-
ever, returned to the initial levels after 1hourof treatment.More-
over, in resistant CSC, anti-EGFR treatment increased the levels of
phospho-BCL2, phospho-JAK2, phospho-MEK1/2, and total
STAT3. Overall, these observations suggest that cetuximab-
sensitive cells undergo a coordinated downregulation ofmultiple
survival pathways (specifically, the PI3K/AKT/MTOR, RAS/MEK/
ERK, and JAK/STAT pathways) upon anti-EGFR treatment. By con-
trast, cetuximab-resistant cellsmay show a transitory decrease in
survival factor activation but shortly recover baseline levels and
may even show a reactive increase in the expression/activation
of some factors at longer times of treatment upon anti-EGFR
blockade.
Effects of Targeted Pathway Inhibition in Anti-EGFR
Sensitive and Resistant CSCs
To further investigate the involvement of pathways identified by
RPPA analysis in CSC survival, we compared the sensitivity of two
CSC lines, one KRASwt (sensitive to anti-EGFR) and one KRASmut,
with that of a panel of inhibitors directed against factors belong-
ing to the three main survival pathways identified through RPPA
analysis (Fig. 7A; supplemental online Table 5). Spheroids were
dissociated 24 hours before treatment, seeded in 96-well plates,
incubated with targeted inhibitors, and viability was assessed af-
ter 72 hours. In KRASwt cells, cetuximab as a single agent induced
approximately a 50% loss of vitality. The combination of cetuximab
with pathway inhibitors was invariably more effective than inhibi-
torsalone in inducingCSCdeath, and, in somecases (particularly for
multiple pathway inhibitors), had a strongly increased effect as
compared with the single drugs (Fig. 7B, top panel). Cetuximab-
resistant CSCs showed a completely different pattern of sensitivity
totargeted inhibitors,beinghighlyresistanttothemajorityofdrugs
tested, either alone or in combination with anti-EGFR (Fig. 7B, bot-
tom panel). However, in cetuximab-resistant CSCs, we observed a
synergy between anti-EGFR and the double PI3K-MTOR inhibitor
PF-05212384 indecreasing cell survival, indicatinga specific vulner-
ability to the combined inhibition of EGFR, PI3K, and MTOR path-
ways (Fig. 7B, bottom panel).
DISCUSSION
The development of faithful in vitro and in vivo models to inves-
tigate the molecular basis of tumor development, progression,
and relapse is a central issue in CRC research [2]. Advancements
made in recent years include patient-derived spheroid cultures,
organoid cultures, xenospheres, patient-derived xenografts,
and short-term cultures of stem cells [15, 25, 27–29]. Each
method of CRC cell isolation, expansion, and culture is associated
with a series of drawbacks encompassing, from time to time, the
emergence of culture-associated changes, genetic biases due to
selective pressures acting during xenograft or culture establish-
ment, low rates of success in cell isolation, inadequate cell expan-
sion, and scarce manageability of cultures for molecular studies.
Several reports have described methods for the isolation of CRC
cells from primary tumors [30–35]. However, the ultimate value
of such methods depends on multiple factors, including cell pu-
rity, presence and quantity of tumor-initiating cells, reproducibil-
ity, and the ability of cultured cells to phenocopy the original
tumor in mice.
We have set up a protocol for CRC cell isolation, expansion,
and characterization that allowed us to create a biobank of mo-
lecularly annotated patient-derived cells enriched in CSCs. Such
cells represent a resource available for in vitro studies and in
vivo evaluations of anticancer drug efficacy in subcutaneous
or metastatic tumors. In comparison with previous methods
used for the establishment of tumor-derived multicellular
spheroid cultures, we have increased the yield of CSC lines from
surgical specimens through an optimization of culture media
and conditions that permits the development of CSC-enriched
lines highly representative of patient tumors in terms of genetic
landscape and drug sensitivity. Although the derivation of
spheroid cultures from surgical specimens has a lower rate of
success than organoid cultures, the resulting populations have
highly increased cell yields and are suitable for studies that re-
quire considerable amounts of cellular materials, such as pro-
teomic or metabolomic arrays. Moreover, tumor spheroids
are easily amenable to genetic modification and can be used
to modulate the expression of putative stem cell genes and to
assess their effects on population dynamics [15]. Importantly,
we show that spheroid cultures retain, at least in part, the ge-
netic heterogeneity of tumors of origin, as demonstrated by
the polyclonality and the complex pattern of mutations present
within single CSC lines. Spheroid lines display heterogeneity also
in terms of differentiated state, as shown by the expression of
surface markers and nuclear b-catenin (revealed by the TOP-
GFP system). The expression of “stem” cell markers (CD133,
CD44v6, and Lgr5) in spheroid cultures suggests that they are
prevalently composed by early progenitors (positive for
CD133) with a significant presence of CSCs (positive for Lgr5
and/or CD44v6) and a fraction of terminally differentiated
(TOP-GFPnegative) cells.
We used spheroid cultures to investigate the impact of
anti-EGFR treatment on the CSC compartment in vivo, to iden-
tify the main pathways affected by anti-EGFR and to perform a
proof-of-principle test of sensitivity to targeted pathway in-
hibitors in combination with cetuximab. In this context, we
found that anti-EGFR treatment in KRASwt/cetuximab-
sensitive xenografts affects both stem and nonstem cells, as
shown by the smaller volume but unvaried percentage of CSCs
found in cetuximab-treated tumors as compared with con-
trols. This is in contrast with the increased CSC content of
chemotherapy-treated tumors, which we found to be effi-
ciently counteracted by the combination with anti-EGFR.
These observations provide a strong rationale for the com-
bined use of cetuximab-chemotherapy combinations, because
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Figure 6. Reverse phase proteomic array (RPPA) for the identification of pathways differently activated in anti-epidermal growth factor
receptor-sensitive and -resistant CSC. (A): Highly responsive (CSC1) and resistant (CSC8) CSC lines were treated with cetuximab and an-
alyzed at different time points by RPPA. Statistical analysis of unsupervised clustering identified 27 endpoints differentially modulated in
CSC1 andCSC8. Time-course plots (B) andWestern blot validation (C)of eight relevant pathway effectors. Abbreviations: CETU, cetuximab;
CSC, cancer stem cell.
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surviving tumor cells should be less aggressive than those
treated with chemotherapy alone.
Proteomic analysis of pathways affected by cetuximab treat-
ment revealed coordinated changes in key factors belonging to
the PI3K/AKT/MTOR, RAS/MEK/ERK, and JAK/STAT pathways
that result in the death of KRASwt/cetuximab-sensitive cells.
The same pathways present time-dependent variations in
KRASmut cells but invariably return to a baseline state and, in
some cases (as for BCL2), to a phosphorylation level higher
than untreated cells, suggesting the possible occurrence
of a reactive antiapoptotic state. Treatment of KRASwt/
cetuximab-sensitive cells with a panel of inhibitors directed
against the PI3K/AKT/MTOR, RAS/MEK/ERK, and JAK/STAT
pathways showed an overall sensitivity to targeted drugs,
which, in several cases, was increased by combination with
cetuximab. By contrast, KRASmut cells were highly resistant
to themajority of targeted drugs and, as predicted by the pres-
ence of constitutively activated KRAS, were insensitive to
cetuximab as a single agent or in combination with pathway
inhibitors. Notably, however, the dual PI3K/MTOR inhibitor
PF-05212384 displayed a synergistic activity with cetuximab
in KRASmut cells, suggesting a potential efficacy in inhibiting
PI3K activity (both downstreamof EGFR and fromother sources)
simultaneously with MTOR inhibition. This observation cor-
roborates the clinical development of PF-05212384 (which
recently showed a manageable safety profile and antitu-
mor activity in phase I clinical trials [36]) and its potential
use in combination with anti-EGFR in therapy-resistant colo-
rectal cancer.
CONCLUSION
In aggregate, our results show that CSC-enriched spheroid cul-
tures faithfully capture important features of primary colorectal
tumors. Even more importantly, we show that CSC lines provide
an efficient experimental system to perform panomic analyses
and preclinical drug testing, thus leading to a deeper understand-
ing of the molecular determinants of therapy resistance and of
the tumor sensitivity to combination therapies.
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